Information Provided By:
Fly News Breaks for June 22, 2018
SLNO
Jun 22, 2018 | 07:26 EDT
Roth Capital analyst Yasmeen Rahimi initiated Soleno Therapeutics with a Buy rating and $14 price target, stating that the company's lead asset, Diazoxide Choline Controlled-Release, has the potential to be a leader in the Prader-Wili Syndrome treatment arena.
News For SLNO From the Last 2 Days
There are no results for your query SLNO
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.